However, the multikinase inhibitor Dasatinib (BMS-354825, SPRYCEL), which targets FAK together with Abl, Src and c-Kit, is under evaluation for rhabdomyosarcoma, neuroblastoma and ewing sarcoma [12]. This evidence concerns the gene PTK2 and sarcoma.